MDLIVE $50 million private placement
Davis Polk advised MDLIVE Inc. in connection with its private placement of approximately $50 million in shares of its Series F preferred stock.MDLIVE offers virtual healthcare services to…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Venus Medtech (Hangzhou) HK$1.2 billion H shares placement
Davis Polk advised Venus Medtech (Hangzhou) Inc. in connection with its placing of 18,500,000 new H shares for an aggregate consideration of approximately HK$1.2 billion (approximately US…
I-Mab $418 million private placement
Davis Polk advised the lead placement agent in connection with I-Mab’s $418 million private placement of 29,133,502 ordinary shares and warrants to subscribe for 5,341,267 ordinary shares…
Royalty Pharma $6 billion senior notes offering
Davis Polk advised Royalty Pharma plc in connection with its Rule 144A/Regulation S offering of $1 billion aggregate principal amount of its 0.75% senior notes due 2023, $1 billion…
Eli Lilly $1.1 billion notes offering
Davis Polk advised the joint book-running managers in connection with a registered offering by Eli Lilly and Company of $1.1 billion aggregate principal amount of senior notes, consisting…
CureVac $245.3 million IPO
Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which includes 1,999,999 common shares from the full exercise of the…
Five Prime Therapeutics $75 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Five Prime Therapeutics, Inc. of its common stock for up to an aggregate amount of $75 million.
Five…
Personalis $125 million stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $125 million public offering of common stock by Personalis, Inc. The common stock…
IDEAYA Biosciences $50 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by IDEAYA Biosciences, Inc. of its common stock for up to an aggregate amount of $50 million.
Based in…
Atreca $100 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Atreca, Inc. of its common stock for up to an aggregate amount of $100 million.
Atreca is a…